The specter of generic rivalry has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of connected drug ventures. While first years saw significant gains, the intellectual property lapse has created the way for discounted substitutes, potentially diminishing profitability and posing a genuine risk… Read More